Press Releases

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

Mar 22, 2023

New agreement integrates Dario's cardiometabolic suite into Amwell's market leading digital care delivery enablement platform covering over 90 million lives

NEW YORK, March 22, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023.

DarioHealth Logo


The agreement is part of Dario's strategy to partner with market leading strategic partners to accelerate adoption of Dario's solutions by making the Dario solution available to existing Amwell customers.  The integration into Amwell will support a more continuous and connected member journey by providing Dario's cardiometabolic solution as part of Amwell's comprehensive portfolio of care solutions and network of affiliated clinicians. Members living with cardiometabolic health concerns such as diabetes, high blood pressure and weight management challenges will have access to Dario's proven and highly personalized digital solution to help better manage their condition and improve outcomes between visits with clinicians practicing on the Amwell platform. Members can access Dario's solutions directly through Amwell's digital care delivery enablement platform to support ease of engagement.

"Amwell is a recognized leader in digital care delivery enablement covering 90 million lives through its substantial footprint of clients. We are proud to partner with them to take the Dario cardiometabolic suite to our target markets," said Rick Anderson, President of Dario. "Leveraging the power of our combined offering to enhance care and support for members, benefits everyone. This partnership fits the clear market demand for more condition solutions from less vendors and lowers the cost of delivering high value innovative digital health for buyers."

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company, revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health. 

Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit

About Amwell

Amwell is a leading digital care delivery enablement platform in the United States and globally, connecting and enabling providers, insurers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that digital care delivery will transform healthcare. The Company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With over a decade of experience, Amwell powers the digital care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation's largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit

©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Conversa®, ConvergeTM, CarepointTM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation. All other trademarks are the property of their respective owners.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected launch of its solution through Amwell, and that the partnership fits the market demand for more condition solutions from less vendors and lowers the cost of delivering high value innovative digital health for buyers. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Mary Mooney
VP Marketing

Media Contact:
Scott Stachowiak


SOURCE DarioHealth Corp.